Efficacy and Safety of GENOSS SES in Patients with Coronary Artery Disease
Launched by GENOSS CO., LTD. · Feb 18, 2025
Trial Information
Current as of July 24, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of a specific type of stent called GENOSS SES in patients with coronary artery disease (CAD). A stent is a small, tube-like device that helps keep the arteries open, allowing blood to flow more freely to the heart. The trial is currently active but not recruiting new participants, meaning they are not looking for more individuals to join at this time.
To be eligible for this trial, patients must be 19 years or older and have been treated with the GENOSS SES stent. They also need to willingly agree to participate, follow the study guidelines, and provide written consent. However, certain individuals cannot participate, including those with specific medical conditions, pregnant women, or those who have recently undergone certain surgeries. Participants can expect to receive close monitoring throughout the study to ensure their safety and to gather information on how well the stent works.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients of 19 and over
- • 2. Patients with coronary artery disease treated with GENOSS SES
- • 3. Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants
- Exclusion Criteria:
- • 1. Patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents
- • 2. Patients who are pregnant or planning to become pregnant
- • 3. Patients with a planned surgery to discontinue antiplatelet agents within 12 months
- • 4. Patients with a life expectancy of less than 1 year
- • 5. Patient with cardiogenic shock at the time of hospitalization and had a low chance of survival based on medical judgment.
- • 6. Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration
- • 7. Patients participating in randomized controlled trials using other medical devices
About Genoss Co., Ltd.
Genoss Co., Ltd. is a pioneering biotechnology company dedicated to advancing healthcare through innovative diagnostic solutions and therapeutics. With a strong focus on developing cutting-edge technologies, Genoss specializes in molecular diagnostics and personalized medicine, aiming to enhance patient care and treatment outcomes. The company is committed to conducting rigorous clinical trials to validate its products and ensure compliance with international regulatory standards. Through collaboration with healthcare professionals and research institutions, Genoss strives to address unmet medical needs and contribute to the future of precision medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seongnam, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported